- Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates
- Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer
- Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates
- Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
- Genelux Corporation Announces New Chief Financial Officer
- Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates
- Genelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2023
- Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires
More ▼
Key statistics
On Wednesday, Genelux Corp (GNLX:NAQ) closed at 4.86, 58.82% above the 52 week low of 3.06 set on Apr 30, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.04 |
---|---|
High | 5.75 |
Low | 4.70 |
Bid | 4.55 |
Offer | 5.92 |
Previous close | 5.02 |
Average volume | 171.70k |
---|---|
Shares outstanding | 27.00m |
Free float | 21.06m |
P/E (TTM) | -- |
Market cap | 135.52m USD |
EPS (TTM) | -0.9811 USD |
Data delayed at least 15 minutes, as of May 22 2024 21:00 BST.
More ▼